A first glance at this hedge fund’s strategic Q2 moves in biotech sector.
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) management hosted a conference call this morning to address Ocaliva safety concerns. As a reminder, company issued a Healthcare …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) provided comment on the Ocaliva (obeticholic acid or OCA) Dear Healthcare Provider (DHCP) letter issued on September 12, 2017, …
Intercept Sank 40% in September following Dear Doctor and FDA warning letters; Ritu Baral weighs in.
Shares of drug maker Intercept Pharmaceuticals Inc (NASDAQ:ICPT) are in a freefall today. Why?
Dear doctor: My shares just fell 15%.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced results from CONTROL, a placebo-controlled trial to prospectively characterize the lipid metabolic effects of obeticholic acid (OCA) and …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) reported financial results for the three months ended March 31, 2017 and provided other general business updates. “I’m very …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares rose as much as 9% during Friday’s trading session, after the drug maker announced changes to its ongoing Ocaliva …
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced that the European Commission has granted conditional approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis …